HDAC9 and plasma cell myeloma: Three HDAC inhibitors (i.e., romidepsin, belinostat, vorinostat) were approved for cutaneous T-cell lymphoma (CTCL), and another HDAC inhibitor, panobinostat, was approved for treating multiple myeloma.